Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 17,178

Document Document Title
WO/2019/173911A1
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-e...  
WO/2019/172210A1
[Problem] To provide a novel compound having great potential as a prodrug-type anticancer agent. [Solution] A compound represented by general formula (I) or a salt thereof  
WO/2019/172834A1
The present invention relates to a process for the preparation of certain 1,5-benzothiazepine compounds, and in particular toa process for the preparation of elobixibat. The process can be carried out under mild and safe conditions and m...  
WO/2019/166347A1
The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility ...  
WO/2018/094023A3
A pharmaceutical composition comprising a cyclo-dipeptide and use thereof for treatment of a wound. The cyclo-dipeptide can be Cyclo-His-Pro and the pharmaceutical composition can suitable for topical application to a wound. The composit...  
WO/2019/167034A1
Non-antimicrobial compounds, methods and compositions comprising the same for treating medical conditions associated with pathogenic microorganism in a subject, as well as drug-resistant strains thereof, which are effective in immunopote...  
WO/2019/168149A1
The present invention addresses the problem of providing: a peptide having an excellent effect to prevent the deterioration in a cognitive function and to improve a cognitive function; and a use of the peptide. In the present invention, ...  
WO/2019/164987A1
Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities t...  
WO/2019/161487A1
Beef protein was hydrolyzed with each of six commercial enzymes (alcalase, chymotrypsin, trypsin, pepsin, flavourzyme, and thermoase). Electronic tongue measurements showed that the hydrolysates had significantly (p < 0.05) lower bitter ...  
WO/2019/160024A1
Provided is a composition for reducing blood pressure and/or reducing neutral fats that has few side effects and is very safe. The composition for reducing blood pressure and/or for reducing neutral fats comprises a casein hydrolysate an...  
WO/2019/160037A1
The purpose of the present invention is to provide methods for producing a carboxamide compound, a sulfonamide compound, and an ester compound using an acid halide. The methods for producing a carboxamide compound, a sulfonamide compound...  
WO/2019/160916A1
Provided herein are heterocyclic compounds useful for imaging Granzyme B. Methods of imaging Granzyme B, combination therapies, and kits comprising the Granzyme B imaging agents are also provided.  
WO/2019/154053A1
Disclosed are a new compound that inhibits IAP and the use thereof. In particular, the present invention relates to a compound which is an IAP inhibitor, or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmace...  
WO/2019/104851A4
Beta-hydroxybutyryl-amino acid compounds represented by formulas I, II, III, IV, V, VI, VII, VIII, IX and X, a preparation method therefor and use thereof. The compounds have antitumor activity and can be used for weight loss, anti-aging...  
WO/2019/156630A1
Disclosed herein is a membrane having less than 15% water content, comprising a modified agarose that is covalently linked to a cell attachment signal such as an amino acid, a peptide and a chemical moiety that cells recognize and intera...  
WO/2019/155464A1
The invention disclosed herein concerns a novel class of compounds suitable for the treatment of neurodegenerative diseases, such as Parkinson's Disease.  
WO/2019/157014A1
A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schi...  
WO/2019/154151A1
The present invention relates to an intermediate compound of formula II-1 or formula II-2 or a salt thereof, and a preparation method therefor. The present invention further relates to a process for synthesizing a compound of formula I b...  
WO/2019/151384A1
One embodiment of the present invention relates to novel substances, etc., which are: [1] a compound, etc., represented by formula (A1) or formula (B1); [2] a compound, etc., represented by formula (A2) or formula (B2); [3] a compound, e...  
WO/2019/151320A1
The problem addressed by the present invention is to provide a technique for improving the anticancer effect of ubenimex, especially the anticancer effect on solid cancers. The problem is solved by a compound containing a chain-form stru...  
WO/2019/151137A1
The purpose of this invention is to provide a substance which, by being added to food, promotes intracerebral discharge of both noradrenaline and serotonin, thereby preventing cranial brain disease and improving brain function. A specifi...  
WO/2017/021004A8
The present invention relates to chromogenic and fluorogenic substrates that can be used for the highly sensitive and selective detection of the activity of serine proteases. The present invention further relates to methods for the detec...  
WO/2019/100004A3
The subject invention provides compositions and methods for alleviating pain. Specifically, the subject invention provides pharmaceutical formulations of polymers, and/or their salts, having advantageous μ-opioid receptor binding activity.  
WO/2019/147182A1
The present invention relates to novel antiatherosclerotic compounds of formula (I), their pharmaceutically acceptable salts, their isomers, and processes for preparing them. The present invention further provides pharmaceutical composit...  
WO/2019/137247A1
The present invention relates to the field of virology, and specifically discloses a short peptide having a dengue virus replication inhibition function and an application thereof. The amino acid sequence of the short peptide provided in...  
WO/2019/104851A3
Beta-hydroxybutyryl-amino acid compounds represented by formulas I, II, III, IV, V, VI, VII, VIII, IX and X, a preparation method therefor and use thereof. The compounds have antitumor activity and can be used for weight loss, anti-aging...  
WO/2019/138355A1
To provide a material that can impart excellent bacterial repelling property to a variety of surfaces. A bacterial repelling composition comprising a structure of a self-organized lipid-peptide compound, wherein the lipid-peptide compoun...  
WO/2019/139126A1
Provided is a sodium taurocholate cotransporting polypeptide (NTCP) inhibitor which comprises a cyclic peptide having an Xw1-W-Xw2-W structure (Xw1 and Xw2 are each independently T, S, I, L, or V, or N-alkyl amino acids thereof) or a P-X...  
WO/2019/134510A1
Disclosed is a short peptide quaternary ammonium salt compound and a use thereof. In particular, disclosed is a type of short peptide quaternary ammonium salt compound or a stereoisomer, polymorph, solvate thereof, or a metabolite, prodr...  
WO/2019/127686A1
The present invention relates to a combined ligand, as well as a combined biomimetic chromatography medium, a preparation method therefor, and application thereof. Regarding the combined biomimetic chromatography medium, a hydrophilic po...  
WO/2019/132351A1
The present invention relates to a peptide for inhibiting skin inflammation, and a pharmaceutical composition and a cosmetic composition each containing the same for prevention or treatment of skin inflammation. The peptide, pharmaceutic...  
WO/2019/133988A1
The proteasome inhibitors of this invention are peptide-based compounds with a short linear sequence of amino acids. A cyclic oxo or thio group is attached to the N terminal amino acid. A protein-reactive electrophilic group such as an e...  
WO/2019/119141A1
The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and...  
WO/2019/119067A1
The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral ...  
WO/2019/123367A1
The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, Z, Y, A, G, D and E have any of the meanings defined herein. This specificatio...  
WO/2019/123331A1
The present invention relates to compounds having the formula [Co-enzyme A or analogue thereof]-Z1-Z2-Z3-Z4, wherein Z1 is a linker, Z2 and Z3 are peptides or peptide-based moieties, and Z4 is a C-terminal group. The invention also provi...  
WO/2019/119117A1
There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis...  
WO/2019/115812A1
The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflamm...  
WO/2019/118878A1
Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.  
WO/2019/116071A1
Compounds for treating neurodegenerative disorders The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders.  
WO/2019/114666A1
The present invention relates to a bioactive conjugate, a preparation method therefor, and use thereof. In particular, the present invention relates to a novel type of bioactive molecular conjugates obtained by improving the coupling of ...  
WO/2019/112630A1
Compositions of foods, vitamin and mineral supplements, topical or oral drugs, and cosmetic products containing a small peptide or peptides for slowing degradation, for example by transition metals. The peptides are di, tri, terra-, and/...  
WO/2019/109188A1
The present application is directed to compounds of Formula (I)-(VI): (I), (II), (III), (IV), (V) (VI), (VII) and (VIII), compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.  
WO/2019/109934A1
The present invention provides a salt of a phenylpropionamide derivative and a preparation method therefor. The present invention specifically provides an acetate, hydrochloride, phosphate, citrate, benzoate, or fumarate of 4-amino-1-((2...  
WO/2019/108974A1
The present disclosure provides for albumin-binding prodrugs of auristatin E derivatives and uses thereof.  
WO/2019/104851A2
Beta-hydroxybutyryl-amino acid compounds represented by formulas I, II, III, Ⅳ, V, VI, VII, VIII, IX and X, a preparation method therefor and use thereof. The compounds have antitumor activity and can be used for weight loss, anti-agin...  
WO/2019/107057A1
[Problem] The purpose of the present invention is to provide a peptide, etc., that is capable of suppressing muscle atrophy. [Solution] A peptide comprising an amino acid sequence represented by any of SEQ ID NOS: 1-13. A composition hav...  
WO/2019/102397A1
A synthesis method for the production of N-acyl glutathione, comprising an acylation step, during which, in a water solution with a pH ranging from 8 to 10, glutathione is caused to react with an anhydride with formula (RCO)2O with a for...  
WO/2019/104318A1
Solid state forms of Ivosidenib, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.  
WO/2019/096870A1
The invention describes a composition containing a) a functionalized polymer (10) that comprises at least one polymer segment (13) and at least two polymer aggregating segments (11,12) capable of forming non-covalent bonds based on a sup...  

Matches 1 - 50 out of 17,178